ERBB2 and cancer: Importantly, as shown for ebselen oxide alone (Fig. 2C,F,I) the combination of these treatments had no effect on the proliferation of non‐HER2‐overexpressing cancer cells such as MDA‐MB‐231 (Fig. S6D).